Should I buy or sell Regulus Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks .

What is Regulus Therapeutics' stock price target for 2024?

2 brokerages have issued twelve-month price targets for Regulus Therapeutics' stock. Their RGLS share price targets range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 650.0% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts .

How have RGLS shares performed in 2023?

Regulus Therapeutics' stock was trading at $1.37 at the start of the year. Since then, RGLS stock has increased by 2.2% and is now trading at $1.40. View the best growth stocks for 2023 here .

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our RGLS earnings forecast .

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.04.

When did Regulus Therapeutics' stock split?

Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com . Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO) , Flexion Therapeutics (FLXN) , Cytori Therapeutics (CYTX) , PTC Therapeutics (PTCT) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) , Gilead Sciences (GILD) , Synergy Pharmaceuticals (SGYP) and Trevena (TRVN) .

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.45%), Victory Capital Management Inc. (1.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Ray Aker , Denis Drygin , Joseph P Hagan and Paul Edward Walker. View institutional ownership trends .

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Regulus Therapeutics Stock Price, News & Analysis (NASDAQ:RGLS)

$1.40

+0.09 (+6.87%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.28
▼
$1.40
50-Day Range: $1.21
▼
$1.44
52-Week Range: $0.76
▼
$2.14

Volume: 9,307 shs
Average Volume: 22,028 shs
Market Capitalization: $28.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Regulus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 650.0% Upside
$10.50 Price Target
Short Interest: Healthy
1.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.85
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.58) to ($1.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

370th out of 953 stocks

Pharmaceutical Preparations Industry

163rd out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Regulus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, Regulus Therapeutics has a forecasted upside of 650.0% from its current price of $1.40.
Amount of Analyst Coverage
Regulus Therapeutics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.04% of the float of Regulus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Regulus Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Regulus Therapeutics has recently decreased by 5.18%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Regulus Therapeutics does not currently pay a dividend.
Dividend Growth
Regulus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RGLS.

2.7

News and Social Media Coverage

News Sentiment
Regulus Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Regulus Therapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for RGLS on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.41% of the stock of Regulus Therapeutics is held by insiders.
Percentage Held by Institutions
62.22% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Regulus Therapeutics are expected to grow in the coming year, from ($1.58) to ($1.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regulus Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regulus Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Regulus Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

RGLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RGLS Stock News Headlines

December 2, 2023 | americanbankingnews.com

Regulus Therapeutics (NASDAQ:RGLS) Share Price Crosses Above 200 Day Moving Average of $1.40

December 2, 2023 | americanbankingnews.com

Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.com

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 24, 2023 | americanbankingnews.com

Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com

November 22, 2023 | finance.yahoo.com

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 11, 2023 | markets.businessinsider.com

Regulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial Progress

November 9, 2023 | finance.yahoo.com

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

November 2, 2023 | finance.yahoo.com

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 19, 2023 | finance.yahoo.com

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

October 5, 2023 | nasdaq.com

Regulus Therapeutics (RGLS) Price Target Increased by 13.64% to 6.38

September 22, 2023 | msn.com

Canaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy Recommendation

September 21, 2023 | markets.businessinsider.com

Analyst Expectations for Regulus Therapeutics's Future

September 20, 2023 | msn.com

Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease

September 20, 2023 | markets.businessinsider.com

Regulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429

September 20, 2023 | finance.yahoo.com

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

September 13, 2023 | finance.yahoo.com

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

September 5, 2023 | finance.yahoo.com

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

August 24, 2023 | gurufocus.com

Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?

August 23, 2023 | finance.yahoo.com

Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

August 23, 2023 | finance.yahoo.com

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

August 9, 2023 | markets.businessinsider.com

Regulus (RGLS) Gets a Buy from H.C. Wainwright

August 8, 2023 | finance.yahoo.com

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

August 2, 2023 | finance.yahoo.com

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

July 18, 2023 | finance.yahoo.com

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

June 28, 2023 | markets.businessinsider.com

Expert Ratings for Regulus Therapeutics

June 28, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Regulus (RGLS)

See More Headlines

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:RGLS
CUSIP: 75915K10
CIK: 1505512
Web: www.regulusrx.com
Phone: (858) 202-6300
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.50
High Stock Price Target: $12.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +650.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -94.24%
Return on Assets: -69.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.25
Quick Ratio: 4.25

Sales & Book Value

Annual Sales: $10.01 million
Price / Sales: 2.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 20,220,000
Free Float: 18,522,000
Market Cap: $28.31 million
Optionable: Optionable
Beta: 1.60

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Joseph P. Hagan M.B.A. (Age 54)
CEO & Director
Comp: $920.73k
Ms. Crispina Calsada CPA (Age 53)
Chief Financial Officer
Comp: $500.87k
Mr. Christopher Ray Aker J.D. (Age 62)
Senior VP, General Counsel & Corporate Secretary
Comp: $524.79k
Dr. Preston S. Klassen M.D. (Age 54)
M.H.S., President and Head of Research & Development
Mr. Daniel J. Penksa (Age 37)
Executive Director of Finance & Controller
Dr. Claire Susan Padgett M.S.
M.T., Ph.D., Senior Vice President of Clinical Operations
Dr. Rekha Garg M.D.
M.S., Senior Vice President of Clinical Development & Regulatory

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RGLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares.
View RGLS analyst ratings or view top-rated stocks.
What is Regulus Therapeutics' stock price target for 2024?: 2 brokerages have issued twelve-month price targets for Regulus Therapeutics' stock. Their RGLS share price targets range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 650.0% from the stock's current price.
View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts.
How have RGLS shares performed in 2023?: Regulus Therapeutics' stock was trading at $1.37 at the start of the year. Since then, RGLS stock has increased by 2.2% and is now trading at $1.40.
View the best growth stocks for 2023 here.
When is Regulus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our RGLS earnings forecast.
How were Regulus Therapeutics' earnings last quarter?: Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.04.
When did Regulus Therapeutics' stock split?: Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?: 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Regulus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).
Who are Regulus Therapeutics' major shareholders?: Regulus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.45%), Victory Capital Management Inc. (1.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends.
How do I buy shares of Regulus Therapeutics?: Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RGLS) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial